• Benjamin S Brooke.
• Department of Surgery, Johns Hopkins Hospital, Baltimore, MD 21287, USA. bbrooke1@jhmi.edu
• J. Vasc. Surg. 2010 Feb 1;51(2):515-9.

AbstractPerioperative beta-blocker therapy has been a heavily investigated and controversial topic during the past decade. Prior national consensus statements that recommended the routine use of these medications in patients undergoing high-risk surgical procedures have been called into question because of the results of recent clinical trials that involved heterogeneous groups of surgical patients. This article reviews the evidence for perioperative beta-blocker usage as it pertains to patients undergoing vascular surgery procedures. The weight of evidence suggests that beta-blockers lower the perioperative risk of myocardial ischemia or infarction and cardiovascular death among patients with clinical risk factors undergoing major vascular surgery. However, there appears to be a concurrent risk of adverse events associated with these medications if patients are not monitored properly during the perioperative period. Perioperative beta-blockers should continue to occupy a prominent role in the therapeutic armamentarium for improving outcomes among high-risk patients undergoing major vascular surgery.Copyright 2010 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

16 keywords...

hide…